Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in Chinese patients

Cellular Physiology and Biochemistry

Volumn 31, Issue 4-5, 2013, Pages 525-531

  Zhang, Shuquan ^a   Hou, Xuwei ^b   Zi, Sihua ^a   Wang, Yankui ^c   Chen, Lijun ^a   Kong, Beihua ^a  

^a SHANDONG UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

Epithelial ovarian carcinoma; Polymorphisms; Receptor for advanced glycation end products; Risk

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ORAL CONTRACEPTIVE AGENT;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CHINESE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 84875844965     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350073     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode E, Thiel F, Chenevix-Trench G, Chang-Claude J, Wang-Gohrke S, Ramus S, Pharoah P, Berchuck A: Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol 2009;3:171-181.
3. Berchuck A, Schildkraut JM, Pearce CL, Chenevix-Trench G, Pharoah PD: Role of genetic polymorphisms in ovarian cancer susceptibility: Development of an international ovarian cancer association consortium. Adv Exp Med Biol 2008;622:53-67.
4. Ma X, Zhang J, Liu S, Huang Y, Chen B, Wang D: Polymorphisms in the casp8 gene and the risk of epithelial ovarian cancer. Gynecol Oncol 2011;122:554-559.
5. Goode EL, White KL, Vierkant RA, Phelan CM, Cunningham JM, Schildkraut JM, Berchuck A, Larson MC, Fridley BL, Olson JE, Webb PM, Chen X, Beesley J, Chenevix-Trench G, Sellers TA: Xenobiotic-metabolizing gene polymorphisms and ovarian cancer risk. Mol Carcinog 2011;50:397-402.
6. Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dork T, Durst M, Eccles DM, Ekici AB, Easton D, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O, Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TV, Harnett P, Rookus M, Heikkinen T, Hein R, Hogdall C, Hogdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G, Kelemen LE, Kiemeney LA, Kjaer SK, Lambrechts D, Lapolla JP, Lazaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, Singer CF, Song H, Stram DO, Sutphen R, Lindblom A, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA: The role of kras rs61764370 in invasive epithelial ovarian cancer: Implications for clinical testing. Clin Cancer Res 2011;17:3742-3750.
7. Schmidt AM, Yan SD, Yan SF, Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000;1498:99-111.
8. Lindsey JB, Cipollone F, Abdullah SM, McGuire DK: Receptor for advanced glycation end-products (rage) and soluble rage (srage): Cardiovascular implications. Diab Vasc Dis Res 2009;6:7-14.
9. Lalla E, Lamster IB, Stern DM, Schmidt AM: Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: Mechanisms and insights into therapeutic modalities. Ann Periodontol 2001;6:113-118.
10. Lu B, Song XL, Jia LY, Song FL, Zhao SC, Jiang Y: [differential expressions of the receptor for advanced glycation end products in prostate cancer and normal prostate]. Zhonghua Nan Ke Xue 2010;16:405-409.
11. Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y: Expression of receptor for advanced glycation end products (rage) and mmp-9 in human pancreatic cancer cells. Hepatogastroenterology 2004;51:928-930.
12. Hirata K, Takada M, Suzuki Y, Kuroda Y: Expression of receptor for advanced glycation end products (rage) in human biliary cancer cells. Hepatogastroenterology 2003;50:1205-1207.
13. Jing R, Cui M, Wang J, Wang H: Receptor for advanced glycation end products (rage) soluble form (srage): A new biomarker for lung cancer. Neoplasma 2010;57:55-61.
14. Tesarova P, Kalousova M, Jachymova M, Mestek O, Petruzelka L, Zima T: Receptor for advanced glycation end products (rage)-soluble form (srage) and gene polymorphisms in patients with breast cancer. Cancer Invest 2007;25:720-725.
15. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H: Receptor for advanced glycation end products (rage) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005;64:92-100.
16. Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, Stolzenberg-Solomon RZ: Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2011;20:1430-1438.
17. Gu H, Yang L, Sun Q, Zhou B, Tang N, Cong R, Zeng Y, Wang B: Gly82ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a chinese population. Clin Cancer Res 2008;14:3627-3632.
18. Krechler T, Jachymova M, Mestek O, Zak A, Zima T, Kalousova M: Soluble receptor for advanced glycation end-products (srage) and polymorphisms of rage and glyoxalase i genes in patients with pancreas cancer. Clin Biochem 2010;43:882-886.
19. Kalousova M, Jachymova M, Mestek O, Hodkova M, Kazderova M, Tesar V, Zima T: Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 2007;22:2020-2026.
20. Kankova K, Zahejsky J, Marova I, Muzik J, Kuhrova V, Blazkova M, Znojil V, Beranek M, Vacha J: Polymorphisms in the rage gene influence susceptibility to diabetes-associated microvascular dermatoses in niddm. J Diabetes Complications 2001;15:185-192.
21. Shi YY, He L: Shesis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005;15:97-98.
22. Gaens KH, Ferreira I, van der Kallen CJ, van Greevenbroek MM, Blaak EE, Feskens EJ, Dekker JM, Nijpels G, Heine RJ, 't Hart LM, de Groot PG, Stehouwer CD, Schalkwijk CG: Association of polymorphism in the receptor for advanced glycation end products (rage) gene with circulating rage levels. J Clin Endocrinol Metab 2009;94:5174-5180.
23. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant PJ, Gregersen PK, Stern DM, Schmidt AM: Rage and arthritis: The g82s polymorphism amplifies the inflammatory response. Genes Immun 2002;3:123-135.
24. Kankova K, Vasku A, Hajek D, Zahejsky J, Vasku V: Association of g82s polymorphism in the rage gene with skin complications in type 2 diabetes. Diabetes Care 1999;22:1745.
25. Prevost G, Fajardy I, Besmond C, Balkau B, Tichet J, Fontaine P, Danze PM, Marre M: Polymorphisms of the receptor of advanced glycation endproducts (rage) and the development of nephropathy in type 1 diabetic patients. Diabetes Metab 2005;31:35-39.
26. Yoon SJ, Park S, Shim CY, Park CM, Ko YG, Choi D, Park HY, Oh B, Kim H, Jang Y, Chung N: Association of rage gene polymorphisms with coronary artery disease in the korean population. Coron Artery Dis 2007;18:1-8.
27. Wang X, Cui E, Zeng H, Hua F, Wang B, Mao W, Feng X: Rage genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC. PLoS One 2012;7:e43734.
28. Xu Q, Xue F, Yuan B, Zhang L, Li J, He Z: The interaction between rage gene polymorphisms and hpv infection in determining the susceptibility of cervical cancer in a chinese population. Cancer Biomark 2012;11:147-153.
29. Jang Y, Kim JY, Kang SM, Kim JS, Chae JS, Kim OY, Koh SJ, Lee HC, Ahn CW, Song YD, Lee JH: Association of the gly82ser polymorphism in the receptor for advanced glycation end products (rage) gene with circulating levels of soluble rage and inflammatory markers in nondiabetic and nonobese koreans. Metabolism 2007;56:199-205.
30. Gao J, Shao Y, Lai W, Ren H, Xu D: Association of polymorphisms in the rage gene with serum crp levels and coronary artery disease in the chinese han population. J Hum Genet 2010;55:668-675.
31. Quirk JT, Kupinski JM: Chronic infection, inflammation, and epithelial ovarian cancer. Med Hypotheses 2001;57:426-428.
32. Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, Koenig KL, Berrino F, Lukanova A, Lokshin AE, Idahl A, Ohlson N, Hallmans G, Krogh V, Sieri S, Muti P, Marrangoni A, Nolen BM, Liu M, Shore RE, Arslan AA: Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2011;20:799-810.